Back to top

Bayer’s Rivaroxaban PAD Study Reaches Completion: What Investors Should Watch Next

Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer’s latest update covers a post???marketing database study titled “Post-Ma...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Bayer Aktiengesellschaft (BAYRY)